{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009702","form_type":"8-K","ticker":"WGRX","cik":"0002030763","company_name":"Wellgistics Health, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.050407+00:00","generated_at":"2026-05-15T15:13:31.463703+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal","bullets":["Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).","Revenue split: 50% to Wellgistics, 50% to PharmTech; term is 36 months unless earlier terminated.","Wellgistics makes preferred EBV pricing available immediately through EinsteinRx AI hub; expects revenue stream beginning Q2 2026.","EBV market forecast to grow from $2.39B in 2025 to $3B in 2030 per The Business Research Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009702","json":"https://secwatch.observer/filing/0001493152-26-009702.json","markdown":"https://secwatch.observer/filing/0001493152-26-009702.md","text":"https://secwatch.observer/filing/0001493152-26-009702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:13:31.463703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7b0deac2d209b04a119f4a7bc74f9448c394286","claim":"Wellgistics Health, Inc. entered into Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063834","ticker":"VTIX","company_name":"Virtuix Holdings Inc.","filed_at":"2026-06-02T13:15:39+00:00","headline":"Virtuix amends warrants to $4.00 exercise price, extends period to July 27, 2026","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063834","json":"https://secwatch.observer/filing/0001213900-26-063834.json","markdown":"https://secwatch.observer/filing/0001213900-26-063834.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/0001213900-26-063834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/ea0292972-8k_virtuix.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On June 1, 2026, Virtuix Holdings Inc. (the “Company”) entered into amendments to each of the following warrants to purchase shares of Class A Common Stock (collectively, the “Warrant Amendments”) with Streeterville Capital, LLC (the “Investor”) amending the exercise price and extending the Reduced Exercise Price Period (as defined below) to each such warrant","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/0001213900-26-063834-index.htm"}},{"accession":"0001213900-26-063767","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-06-02T10:30:41+00:00","headline":"Bluejay Diagnostics partners with Argonaut for US-based Symphony platform manufacturing","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063767","json":"https://secwatch.observer/filing/0001213900-26-063767.json","markdown":"https://secwatch.observer/filing/0001213900-26-063767.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/ea0293118-8k_bluejay.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s SymphonyTM platform.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm"}},{"accession":"0001683168-26-004424","ticker":"LTRX","company_name":"LANTRONIX INC","filed_at":"2026-06-01T20:15:28+00:00","headline":"Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004424","json":"https://secwatch.observer/filing/0001683168-26-004424.json","markdown":"https://secwatch.observer/filing/0001683168-26-004424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/lantronix_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm"}},{"accession":"0001493152-26-022133","ticker":"BNAI","company_name":"Brand Engagement Network Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"BEN invests $1M in Accelevate, signs exclusive Mexico reseller and global deal","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022133","json":"https://secwatch.observer/filing/0001493152-26-022133.json","markdown":"https://secwatch.observer/filing/0001493152-26-022133.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/0001493152-26-022133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On May 7, 2026, following the successful completion of due diligence, entered into two definitive Reseller Agreements (the “Commercial Agreements”) with Accelevate.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/0001493152-26-022133-index.htm"}},{"accession":"0001213900-26-053475","ticker":null,"company_name":"MEDICAL EXERCISE INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Medical Exercise signs first franchise agreement for Canadian OnCore Longevity Center","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053475","json":"https://secwatch.observer/filing/0001213900-26-053475.json","markdown":"https://secwatch.observer/filing/0001213900-26-053475.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/0001213900-26-053475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/ea0289708-8k_medical.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On May 6, 2026, Medical Exercise Inc. (the “Company”) entered into a Franchise Agreement (the “Agreement”) with Degco Fitness Ventures Ltd., a corporation based in Regina, Saskatchewan, Canada.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/0001213900-26-053475-index.htm"}},{"accession":"0001493152-26-026890","ticker":"XWIN","company_name":"XMax Inc.","filed_at":"2026-06-02T20:30:36+00:00","headline":"XMax raises $3.6M via private placement of 486,500 shares at $7.347/share","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026890","json":"https://secwatch.observer/filing/0001493152-26-026890.json","markdown":"https://secwatch.observer/filing/0001493152-26-026890.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/0001493152-26-026890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/0001493152-26-026890-index.htm"}},{"accession":"0001193125-26-253506","ticker":"JAGX","company_name":"Jaguar Health, Inc.","filed_at":"2026-06-02T20:10:13+00:00","headline":"Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8","event_type":"other_material","sec_items":["1.01","3.02","8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253506","json":"https://secwatch.observer/filing/0001193125-26-253506.json","markdown":"https://secwatch.observer/filing/0001193125-26-253506.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/d95782d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm"}},{"accession":"0001193125-26-252560","ticker":"CURB","company_name":"Curbline Properties Corp.","filed_at":"2026-06-02T12:07:02+00:00","headline":"Curbline Properties enters up to $400M ATM equity offering; prior program terminated","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252560","json":"https://secwatch.observer/filing/0001193125-26-252560.json","markdown":"https://secwatch.observer/filing/0001193125-26-252560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/0001193125-26-252560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/d111894d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm","comparable_excerpt":"On June 2, 2026, Curbline Properties Corp. (the “ Company ”) and Curbline Properties LP (the “ Operating Partnership ”) entered into an ATM Equity Offering Sales Agreement (the “ Equity Sales Agreement ”) with Jefferies LLC, BNY Mellon Capital Markets, LLC, BofA Securities, Inc., BTIG, LLC, Capital One Securities, Inc., Goldman Sachs & Co. LLC, KeyBanc Capital Markets Inc., Morgan Stanley & Co. LLC, Nomura Securities International, Inc., StoneX Financial Inc. and Wells Fargo Securities, LLC, as sales agents","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/0001193125-26-252560-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}